Ovarian cancer is the most lethal gynecologic malignancy. Surgery and chemotherapy are
the primary treatments for ovarian cancer; however, patients often succumb to recurrence …

Oncolytic viruses can be usefully integrated into tumour immunotherapies, as they target
multiple steps within the cancer–immunity cycle. Oncolytic viruses directly lyse tumour cells …

To effectively build on the recent successes of immune checkpoint blockade, adoptive T cell
therapy and cancer vaccines, it is critical to rationally design combination strategies that will …

Oncolytic viruses (OVs) infect, multiply, and finally remove tumor cells selectively, causing no
damage to normal cells in the process. Because of their specific features, such as, the ability …

Oncolytic viruses (OVs) represent a new class of cancer immunotherapeutics. Administration
of OVs to cancer-bearing hosts induces two distinct immunities: antiviral and antitumor …

Mounting evidence over the past 20 years suggests that photodynamic therapy (PDT), an
anticancer modality known mostly as a local treatment, has the capacity to invoke a systemic …

Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy
cells through a multi-modal mechanism of action. While historically the direct killing activity …

As a promising therapeutic strategy, oncolytic virotherapy has shown potent anticancer
efficacy in numerous pre-clinical and clinical trials. Oncolytic viruses have the capacity for …

Pelareorep causes oncolysis in tumor cells with activated Ras. We hypothesized that
pelareorep would have efficacy and immunomodulatory activity in metastatic pancreatic …

Background Oncolytic viruses reduce tumor burden in animal models and have generated
promising results in clinical trials. However, it is likely that oncolytic viruses will be more …